Novartis sees off ICC claim over pain relief drug
A US subsidiary of Swiss pharmaceuticals group Novartis has defeated a US$82 million ICC claim brought by a former Japanese partner over its decision to discontinue development of a pain relief drug.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.